Semax Peptide: Nootropic Benefits, Dosing, and What the Research Shows

What Is Semax?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic peptide consisting of seven amino acids. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and has been used clinically in Russia since the early 1990s [1]. The peptide is derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH), but it has been modified so that it does not retain ACTH’s hormonal activity. In other words, Semax does not stimulate the adrenal glands or affect cortisol levels at therapeutic doses.

In Russia, Semax has been approved for several clinical indications, including the treatment of cerebrovascular diseases (particularly stroke recovery), cognitive disorders, peptic ulcers, and optic nerve diseases [2]. It is sold as a 0.1% nasal spray solution under various brand names. A stronger formulation (1%) is used specifically for stroke treatment in hospital settings.

Outside of Russia and a few neighboring countries, Semax does not have regulatory approval. In the United States, it occupies a gray area: not FDA-approved, but accessible through some compounding pharmacies and online peptide suppliers. Despite this regulatory gap, Semax has attracted significant interest in the nootropics and biohacking communities due to its cognitive-enhancing and anxiolytic properties.

How Semax Works: Mechanisms of Action

Semax’s neurological effects appear to stem from several interconnected mechanisms. Understanding these pathways helps explain the peptide’s diverse reported benefits.

BDNF Upregulation

Perhaps the most well-documented mechanism of Semax is its ability to increase brain-derived neurotrophic factor (BDNF) expression. BDNF is a protein that plays a critical role in neuronal survival, synaptic plasticity, learning, and memory [3]. Low BDNF levels have been associated with depression, cognitive decline, and neurodegenerative diseases.

Animal studies have shown that Semax can increase BDNF mRNA expression in the hippocampus and cortex, regions essential for memory formation and executive function. This BDNF-boosting effect is considered one of the primary drivers of Semax’s cognitive benefits and may also contribute to its neuroprotective properties [4].

Dopamine and Serotonin Modulation

Semax has been shown to influence several neurotransmitter systems. Research indicates it modulates dopaminergic signaling, which is involved in motivation, reward, focus, and executive function. Studies in animal models have demonstrated that Semax affects dopamine turnover and receptor sensitivity in key brain regions [5].

The peptide also appears to interact with the serotonergic system, which regulates mood, anxiety, and emotional processing. This dual modulation of dopamine and serotonin may explain why users commonly report both cognitive sharpening (a dopaminergic effect) and reduced anxiety (often associated with serotonergic activity).

Neuroprotection and Anti-Inflammatory Effects

In models of cerebral ischemia (stroke), Semax has demonstrated significant neuroprotective activity. The peptide appears to reduce oxidative stress, inhibit inflammatory cascades, and promote the survival of neurons in oxygen-deprived tissue [6]. These effects have been observed at the gene expression level, with Semax influencing hundreds of genes related to immune response, vascular function, and cell survival following ischemic injury.

A genome-wide transcriptional analysis in rats found that Semax affected the expression of genes involved in the immune system, vascular system, and cellular stress responses following focal brain ischemia [7]. The breadth of this gene expression modulation suggests that Semax’s neuroprotective effects go beyond a single pathway.

Nerve Growth Factor (NGF) Effects

Beyond BDNF, Semax has been shown to influence other neurotrophins, including nerve growth factor (NGF). NGF is critical for the maintenance and survival of peripheral and central neurons. By supporting multiple neurotrophic pathways, Semax may provide broad neuronal support rather than acting through a single narrow mechanism [8].

Research on Cognitive Enhancement

Semax’s reputation as a nootropic rests on both published research and extensive clinical use in Russia. The evidence base, while not meeting Western clinical trial standards for most indications, is more substantial than what exists for many other nootropic peptides.

Animal Studies

Numerous studies in rodents have demonstrated that Semax improves performance on learning and memory tasks. In Morris water maze tests (a standard measure of spatial memory in rats), animals treated with Semax showed faster learning curves and better retention compared to controls [9]. These cognitive effects appear to be dose-dependent and are associated with the BDNF and neurotransmitter changes described above.

Human Clinical Data

Published human studies on Semax come primarily from Russian medical literature. While some of these studies have methodological limitations by Western standards (small sample sizes, lack of blinding in some cases), the collective body of evidence is notable.

Clinical studies have reported benefits in:

• Cognitive performance in healthy individuals: Improved attention, memory consolidation, and mental stamina during cognitively demanding tasks [10]
• Stroke recovery: Faster neurological recovery and improved outcomes when administered within the first hours and days after ischemic stroke [11]
• Cognitive decline: Improvements in cognitive function in patients with cerebrovascular disease and mild cognitive impairment
• Optic nerve disorders: Improved visual function in patients with optic nerve atrophy when used as a nasal spray [12]

Limitations of Current Evidence

Most human studies on Semax were conducted in Russia and published in Russian-language journals, which limits accessibility and independent verification. Large-scale, double-blind, placebo-controlled trials meeting international standards are still needed to confirm the benefits observed in smaller studies. The absence of FDA approval reflects this evidence gap for Western regulatory purposes, not necessarily a lack of therapeutic potential.

Anxiety and Mood Effects

Beyond pure cognitive enhancement, Semax has shown anxiolytic (anxiety-reducing) properties in both animal and human studies. This is particularly interesting because many stimulant-type cognitive enhancers tend to increase anxiety as a side effect.

Animal studies suggest that Semax’s anxiolytic effects may be related to its modulation of the enkephalinase system, which is involved in pain perception and emotional regulation [13]. Users commonly describe Semax as providing mental clarity and focus without the jitteriness or anxiety that can accompany caffeine or amphetamine-based cognitive enhancers.

This combination of cognitive enhancement with anxiety reduction makes Semax somewhat unusual in the nootropic landscape. Most compounds that increase dopaminergic signaling tend to be activating and potentially anxiogenic; Semax appears to achieve cognitive sharpening while simultaneously reducing anxiety, likely through its parallel effects on serotonergic and neurotrophic systems.

Nasal Spray Delivery

Semax is most commonly administered as a nasal spray. This delivery route offers several advantages for a peptide targeting the brain.

Why Nasal?

The nasal mucosa provides a relatively direct pathway to the central nervous system. The olfactory and trigeminal nerve pathways that line the nasal cavity allow certain molecules to bypass the blood-brain barrier (at least partially), potentially delivering the peptide more efficiently to brain tissue than systemic injection would [14]. For a peptide whose target is the brain rather than peripheral tissues, nasal delivery makes physiological sense.

Administration

Standard nasal spray administration involves:

1. Clearing the nasal passages before administration
2. Tilting the head slightly forward
3. Inserting the spray tip into one nostril
4. Administering one to two sprays per nostril as directed
5. Avoiding sniffing forcefully (gentle breathing is preferred)
6. Alternating nostrils between doses when possible

Each spray from a standard 0.1% Semax solution delivers approximately 50 mcg of peptide. Practitioners recommend waiting a few minutes between sprays in each nostril to allow for absorption.

Dosing Protocols

Dosing recommendations for Semax vary based on the indication, the formulation concentration, and the prescribing practice. The following are general ranges drawn from clinical use and practitioner protocols.

Standard Nootropic/Cognitive Dose

• Low dose: 200 mcg per day (2 sprays of 0.1% solution, one per nostril)
• Standard dose: 300 to 600 mcg per day, divided into 2 to 3 administrations
• Higher dose: 600 to 900 mcg per day (less common, used by some practitioners for more significant cognitive complaints)

Cycling

Many practitioners recommend cycling Semax, with common protocols including:

• 10 to 20 days on, followed by a 10-day break
• 5 days on, 2 days off (weekday dosing)
• 4 weeks on, 1 to 2 weeks off

The rationale for cycling is to prevent receptor downregulation and maintain sensitivity to the peptide’s effects. Some users report that continuous daily use leads to diminishing returns over time, while cycling preserves the subjective cognitive benefits.

Modified Forms

Two modified versions of Semax deserve mention:

• N-Acetyl Semax (NASA): An acetylated form reported to have enhanced bioavailability and longer-lasting effects. Some users prefer this version for its potentially smoother onset and extended duration.
• N-Acetyl Semax Amidate (NASA-Amidate): A further modification with both acetylation and amidation, reported to be the most potent form. This version is primarily available through research chemical suppliers rather than compounding pharmacies.

Side Effects and Safety

Semax has a favorable safety profile based on decades of clinical use in Russia and published research.

Commonly Reported Side Effects

• Nasal irritation or dryness (the most frequently reported complaint)
• Mild headache (typically at the beginning of use)
• Hair shedding (reported by some users, possibly related to changes in neurotrophic factor signaling, though this is not well-documented in published literature)

Serious Adverse Events

No serious adverse events have been reported in published clinical studies at standard doses [15]. Russian pharmacovigilance data from years of clinical use has not revealed significant safety concerns, though the completeness and accessibility of this data may not meet all Western standards.

What About Cortisol?

A common concern is whether Semax, as a derivative of ACTH, might affect cortisol levels. The available evidence suggests it does not. The modifications made to the ACTH(4-10) fragment to create Semax specifically eliminated its adrenocorticotropic activity. Studies measuring cortisol and ACTH levels after Semax administration have not shown significant hormonal changes at therapeutic doses.

Semax vs. Selank: How They Compare

Selank is another Russian-developed peptide frequently compared to Semax. While Semax is derived from ACTH(4-10), Selank is derived from tuftsin, a naturally occurring immune-regulating peptide.

The key distinction is their primary emphasis. Semax leans toward cognitive enhancement, focus, and neuroprotection through BDNF and dopamine modulation. Selank leans toward anxiolytic and immunomodulatory effects through GABA modulation and immune system regulation.

If the primary goal is cognitive sharpening and mental clarity, Semax is typically preferred. If the primary concern is anxiety or stress management, Selank may be more appropriate. Some practitioners prescribe both together, as their mechanisms are complementary. Both are well-tolerated; Selank tends to be more calming, while Semax can be mildly activating.

Legal Status and Availability

Semax’s legal status varies by country:

• Russia and former Soviet states: Approved as a prescription medication for multiple indications
• United States: Not FDA-approved. Available through some compounding pharmacies (with a prescription) and through online research chemical suppliers (labeled “for research use only”)
• European Union: Not approved by the EMA. Legal status varies by individual country
• Canada: Not approved by Health Canada
• Australia: Not approved by the TGA. Classified as a prescription-only substance

In the United States, Semax is not a controlled substance, meaning possession is not illegal. However, obtaining it without a prescription from an unregulated source carries the quality and purity risks discussed elsewhere in this article and on this site.

Practical Considerations

Storage

Reconstituted Semax nasal spray should be stored in the refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Most formulations maintain potency for 2 to 4 weeks after opening. Keep the bottle tightly capped and away from light.

Timing

Most users find morning and early afternoon dosing optimal, as Semax can have mildly stimulating effects that might interfere with sleep if taken late in the day.

Related Reading

• Peptide Therapy: Complete Guide
• Peptide Injections: What to Know Before Starting
• Are Peptides Safe? Understanding Risks and Benefits
• BPC-157 Dosage: Protocols and Research

References

1. Ashmarin IP, Nezavibatko VN, Levitskaya NG, Koshelev VB, Kamensky AA. “Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and possessing nootropic properties.” Neurosci Res Commun. 1995;16(2):105-112.
2. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochem Res. 2005;30(12):1493-1500. doi:10.1007/s11064-005-8826-8
3. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Res. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108
4. Iasnetsov VV, Voronina TA, Krivitskaia GN. “Effects of Semax on the content of biogenic amines and their metabolites in the brain structures of rats with experimental Parkinsonism.” Aviakosm Ekolog Med. 2013;47(5):44-48.
5. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochem Res. 2005;30(12):1493-1500. doi:10.1007/s11064-005-8826-8
6. Starostin VI, Sviridova TP, Levitskaya NG, Kamensky AA. “Neuroprotective effects of Semax in conditions of global cerebral ischemia in Mongolian gerbils.” Bull Exp Biol Med. 2006;141(4):426-429. doi:10.1007/s10517-006-0183-1
7. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228
8. Agapova TY, Agniullin YV, Silachev DN, Shadrina MI, Slominsky PA, Shram SI, Myasoedov NF. “Effect of Semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus after global ischemia.” Mol Biol. 2008;42(5):684-691.
9. Levitskaya NG, Glazova NY, Sebentsova EA, Manchenko DM, Andreeva LA, Myasoedov NF. “Nootropic and anxiolytic effects of heptapeptide selank in conditions of unpredictable chronic mild stress in rats.” Dokl Biol Sci. 2008;421:271-273. doi:10.1134/S0012496608040121
10. Kaplan AY, Kochetova AG, Nezavibathko VN, Rzhevsky SA, Ashmarin IP. “Synthetic ACTH analogue semax displays nootropic-like activity in humans.” Neurosci Res Commun. 1996;19(2):115-123. doi:10.1002/(SICI)1520-6769(199609)19:2<115::AID-NRC171>3.0.CO;2-B
11. Gusev EI, Skvortsova VI, Izykenova GA, Alekseev AA, Dambinova SA. “The level of autoantibodies to glutamate receptors in the blood serum of patients in the acute period of ischemic stroke treated with Semax.” Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(8):30-34.
12. Polunin GS, Nurieva SM, Baiandin DL, Sheremet NL, Andreeva LA. “Evaluation of therapeutic effect of new Russian drug Semax in optic nerve diseases.” Vestn Oftalmol. 2000;116(1):15-18.
13. Aseeva EN, Lyubimov BI, Guseva MR, Alyautdin RN. “Semax, a synthetic analogue of ACTH(4-10), inhibits development of chronic cerebral ischemia in rats.” Bull Exp Biol Med. 2005;139(4):437-440. doi:10.1007/s10517-005-0316-2
14. Illum L. “Nasal drug delivery: possibilities, problems, and solutions.” J Control Release. 2003;87(1-3):187-198. doi:10.1016/S0168-3659(02)00363-2
15. Bashkatova VG, Koshelev VB, Fadyukova OE, et al. “Novel nootropic peptide Semax does not alter motor activity in rat.” Neuro Endocrinol Lett. 2001;22(6):431-435.